A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer

• Status: Terminated
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety and efficacy of second-line treatment with Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the second line treatment of advanced colorectal cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Treatments: Metformin

Criteria

Inclusion Criteria:

• age over 18

• histologically confirmted advanced colorectal cancer

• ECOG PS 0-2

• expected life span more than 3months

• normal bone marrow, liver, renal function

Exclusion Criteria:

• 5-FU, oxaliplatin, irinotecan or Metformin Allergic history

• Lactic acidosis, metabolic acidosis

• active infection or severe neuropathy